Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2019-02-04 Capital/Financing Update
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Zawarcie istotnych umów pożyczek - Content (PL)
Capital/Financing Update Classification · 98% confidence The document details the execution of significant loan agreements ('istotne umowy pożyczek') by the Issuer (Pharmena S.A.) with related parties (a leading shareholder, the CEO, and the Chairman of the Supervisory Board). The purpose of these loans is explicitly stated as bridging finance ('finansowania pomostowego') to fund the strategy for launching dietary supplements and financing research for TRIA-662, pending a future Series E share issuance. This clearly relates to the company's fundraising, financing activities, and capital structure management. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is a formal report detailing the financing event, not just an announcement of a report (RPA/RNS).
2019-02-04 Polish
190116_zawiadomienie_Max Welt Holdings Ltd i Max Welt Holdings LP
Major Shareholding Notification Classification · 99% confidence The document is titled "ZAWIADOMIENIE W TRYBIE ART. 69 UST. 1 USTAWY O OFERCIE" (Notification under Article 69(1) of the Public Offering Act) and details changes in share ownership (acquisition and disposal of shares/subscription rights) by related parties (Max Welt Holdings Limited and Max Welt Holdings LP) to the Polish financial regulator (Komisja Nadzoru Finansowego). This type of filing specifically reports changes in significant shareholdings, crossing ownership thresholds. This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal notification, not a full report or a general regulatory filing.
2019-01-17 Polish
Ujawnienie stanu posiadania - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is very short (605 characters) and explicitly states that it is reporting the receipt of two notifications (zawiadomienia) under Article 69(1) of the Polish Public Offering Act, concerning changes in significant shareholdings (implied by the reference to Art. 69, which typically deals with major shareholding notifications). Crucially, it states that these notifications 'constitute an attachment to this report' ('Powyższe zawiadomienia stanowią załącznik do niniejszego raportu'). This structure—a brief announcement stating that the actual detailed information (the notifications) is attached or included—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content specifically relates to changes in share ownership thresholds, the most precise category among the options that cover shareholding changes is Major Shareholding Notification (MRQ). However, because this document is merely announcing the *receipt* of the actual notifications and refers to them as attachments, it functions as a publication announcement. Given the specific nature of the content (shareholding changes) and the short length, it is most likely a regulatory filing announcing the receipt of a major holding change report. If the content *was* the actual notification, it would be MRQ. As it is an announcement *about* receiving the notification, and it doesn't fit perfectly into RPA (which usually announces the release of a company report), RNS (General Regulatory Filing) is the safest fallback for specific regulatory disclosures that don't match other codes, or MRQ if we interpret the announcement itself as the required disclosure event. Given the context of Polish law (Art. 70 pkt. 1 referencing Art. 69), this is a mandatory disclosure regarding a change in significant share ownership. Therefore, MRQ (Major Shareholding Notification) is the most appropriate specific code, even if the document is brief.
2019-01-17 Polish
: Zawarcie istotnej umowy kredytowej z BGK - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text, written in Polish, describes the execution of a revolving credit agreement (umowa o kredyt odnawialny) for 2,000,000.00 PLN, detailing the terms, interest rate (WIBOR 3M + margin), maturity date (Dec 31, 2019), and collateral (promissory note, bank account authorization, pledge on inventory, assignment of receivables). The final paragraph explicitly states that the information is being published due to the significance of the agreement for financing the issuer's current operational activities. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). The document is substantive, not just an announcement of a report.
2019-01-15 Polish
Zawarcie umowy licencyjnej ze spółka zależną Menavitin GmbH - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document is written in Polish and discusses a licensing agreement (umowa licencyjna) entered into by the Issuer (PHARMENA S.A.) with its subsidiary regarding the use of a molecule (1-MNA) and trademarks for dietary supplements in Germany, Austria, and Switzerland. It references previous current reports (raport bieżący) concerning strategy and regulatory approvals. This type of announcement, detailing a significant business transaction (licensing agreement) that impacts future revenue and strategy, is typically classified as a material event disclosure. Since it is not a standard periodic report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it relates to business operations and potential revenue impact, it fits best under the general category for regulatory announcements that are material, which is often covered by 'Regulatory Filings' (RNS) in systems where specific transaction codes are absent, or sometimes under 'Capital/Financing Update' (CAP) if it were about raising funds, but here it is a licensing deal. Given the options, and that this is a specific, material business update not covered by the other specific codes (like DIRS, DIV, DLST), RNS (Regulatory Filings) serves as the most appropriate general disclosure category for non-standard material events in this context, especially since the text structure resembles a standard regulatory filing announcement (Raport Bieżący). However, upon re-evaluating the definitions, this is a significant business development/transaction. If a specific 'Material Event Disclosure' code existed, it would be preferred. Since it details a licensing agreement impacting future sales and strategy, and it is not a proxy, audit, or management report, RNS is the best fit as a general regulatory disclosure.
2019-01-03 Polish
PHR_Wykaz akcjonariuszy posiad. pow. 5% głosów na NWZ w dniu 19 12 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text is titled 'Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym Walnym Zgromadzeniu Pharmena S.A. w dniu 19.12.2018 r.', which translates to 'List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of Pharmena S.A. on 19.12.2018'. This document explicitly details the voting results and the percentage of votes held by major shareholders during a General Meeting (ZWZ/EGM). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and contains the final results, not an announcement of a future meeting or a proxy solicitation.
2018-12-20 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.